Francesco Antonica

Francesco Antonica

Auto-generated profile, based on publicly available information

Francesco Antonica

Armenise-Harvard Laboratory of Brain Disorders and Cancer, Department CIBIO, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2012 in Nature
Verified
Journal Article
Closed access
PDF file
FAFrancesco Antonica
Francesco Antonica
DKDominika Figini Kasprzyk
Dominika Figini Kasprzyk
RORobert Opitz
Robert Opitz
MIMichelina Iacovino
Michelina Iacovino
XLXiao-Hui Liao
Xiao-Hui Liao
SCSabine Costagliola
Sabine Costagliola

4 November 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LALuigi Aloia
Luigi Aloia
MMMikel Mckie
Mikel Mckie
GVGrégoire Vernaz
Grégoire Vernaz
LCLucía Cordero-Espinoza
Lucía Cordero-Espinoza
NANiya Aleksieva
Niya Aleksieva
MHMeritxell Huch
Meritxell Huch

12 February 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MBMarco Bonomi
Marco Bonomi
MBMarta Busnelli
Marta Busnelli
PBPaolo Beck-Peccoz
Paolo Beck-Peccoz
DCDaniela Costanzo
Daniela Costanzo
FAFrancesco Antonica
Francesco Antonica
LPLuca Persani
Luca Persani
We report on a family with recessive resistance to the action of thyrotropin-releasing hormone (TRH) due to a nonsense homozygous mutation in the TRH receptor (TRHR) gene (p.R17X). We examined the in vivo effects of complete refractoriness to the TRH signal in this family ( Figure 1 ).

1 December 2012 in Developmental Biology
Verified
Journal Article
Closed access
RORobert Opitz
Robert Opitz
EMEmilie Maquet
Emilie Maquet
JHJan Huisken
Jan Huisken
FAFrancesco Antonica
Francesco Antonica
ATAchim Trubiroha
Achim Trubiroha
SCSabine Costagliola
Sabine Costagliola

15 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FAFrancesco Antonica
Francesco Antonica
LSLucia Santomaso
Lucia Santomaso
DPDavide Pernici
Davide Pernici
LPLinda Petrucci
Linda Petrucci
GAGiuseppe Aiello
Giuseppe Aiello
LTLuca Tiberi
Luca Tiberi
Pediatric and adult high-grade gliomas are the most common primary malignant brain tumors, with poor prognosis due to recurrence and tumor infiltration after therapy. Quiescent cells have been implicated in tumor recurrence and treatment resistance, but their direct visualization and targeting remain challenging, precluding their mechanistic study. Here, we identify a population of malignant cells expressing Prominin-1 in a non-proliferating state in pediatric high-grade glioma patients. Using a genetic tool to visualize and ablate quiescent cells in mouse brain cancer and human cancer organoids, we reveal their localization at both the core and the edge of the tumors, and we demonstrate that quiescent cells are involved in infiltration of brain cancer cells. Finally, we find that Harmine, a DYRK1A/B inhibitor, partially decreases the number of quiescent and infiltrating cancer cells. Our data point to a subpopulation of quiescent cells as partially responsible of tumor invasiveness, one of the major causes of brain cancer morbidity.

1 January 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DCDavide Calebiro
Davide Calebiro
GGGiulia Gelmini
Giulia Gelmini
DCDaniela Cordella
Daniela Cordella
MBMarco Bonomi
Marco Bonomi
FWFranziska Winkler
Franziska Winkler
LPLuca Persani
Luca Persani
Context: Heterozygous mutations in the TSH receptor gene (TSHR) are associated with partial TSH resistance, characterized by isolated nonautoimmune hyperthyrotropinemia (NAHT). The prevalence and management of this condition is controversial. Objective: Our objective was to investigate the prevalence and clinical impact of TSHR alterations in a large series of pediatric patients with NAHT and to dissect their mechanism of action. Design and Setting: For this prospective multicenter study, clinical data and samples were collected in the clinical units and conveyed to a centralized laboratory for analysis. Patients: Subjects included 153 unrelated patients with NAHT aged <18 yr. Exclusion criteria included thyroid dysgenesis or major associated congenital defects. Main Outcome Measures: Parameters of thyroid function, TSHR gene analysis, and TSHR functional assays were evaluated. Results: The frequency of heterozygous nonpolymorphic TSHR variations was 11.8%. We identified seven previously unknown variations: a frameshift (p.Q33PfsX46), one intronic (g.IVS4+2A→G), and five novel missense (p.P162L, p.Y466C, p.I583T, p.I607T, and p.R609Q) variations. The missense variations variably affected TSHR membrane expression and Gs and/or Gq/11 signaling. Several variations cosegregated with NAHT in the affected families. Parameters of thyroid function were similar between affected and unaffected family members. Conclusions: Nonpolymorphic alterations in the TSHR gene are commonly associated with isolated NAHT in young patients, thus configuring partial TSH resistance as the most frequent inheritable cause of isolated NAHT. The identification of TSHR defects may thus be helpful for a tailored management of subclinical hypothyroidism. We provide further evidence that besides the well-known defects in Gs signaling, TSHR genetic alternations found in NAHT may frequently impair the Gq/11 pathway.